Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Zbinden

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
ALTEX|January 1, 1997
[Target proteins and mechanisms of ochratoxin toxicity. A contribution to the identification of potential ochratoxin antagonists]Angelo Vedani, Peter Zbinden
Drug Discovery Today|April 15, 2004
The evolution of microarrayed compound screeningMichael Hoever, Peter Zbinden
Methods in Molecular Biology (Clifton, N.J.)|May 29, 2019
Frontier Between Cyclic Peptides and MacrocyclesPhilipp Ermert, Anatol Luther, Peter Zbinden, et al.
Journal of Biomolecular Screening|February 14, 2008
Use of FLIPR membrane potential dyes for validation of high-throughput screening with the FLIPR and microARCS technologies: identification of ion channel modulators acting on the GABA(A) receptorChristoph Joesch, Emelie Guevarra, Serge P Parel, et al.
Combinatorial Chemistry & High Throughput Screening|December 8, 2004
High throughput screening of beta-amyloid secretion inhibitors using homogenous time-resolved fluorescenceHugo Albrecht, Peter Zbinden, Andrea Rizzi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 12, 2005
Metabolism and disposition of imatinib mesylate in healthy volunteersHans-Peter Gschwind, Ulrike Pfaar, Felix Waldmeier, et al.
Science Advances|May 24, 2023
Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant EnterobacteriaceaeMatthias Schuster, Emile Brabet, Kathryn K Oi, et al.
Nature|November 24, 2019
Author Correction: Chimeric peptidomimetic antibiotics against Gram-negative bacteriaAnatol Luther, Matthias Urfer, Michael Zahn, et al.
Nature|October 25, 2019
Chimeric peptidomimetic antibiotics against Gram-negative bacteriaAnatol Luther, Matthias Urfer, Michael Zahn, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
ALTEX|January 1, 1997
[Target proteins and mechanisms of ochratoxin toxicity. A contribution to the identification of potential ochratoxin antagonists]Angelo Vedani, Peter Zbinden
Drug Discovery Today|April 15, 2004
The evolution of microarrayed compound screeningMichael Hoever, Peter Zbinden
Methods in Molecular Biology (Clifton, N.J.)|May 29, 2019
Frontier Between Cyclic Peptides and MacrocyclesPhilipp Ermert, Anatol Luther, Peter Zbinden, et al.
Journal of Biomolecular Screening|February 14, 2008
Use of FLIPR membrane potential dyes for validation of high-throughput screening with the FLIPR and microARCS technologies: identification of ion channel modulators acting on the GABA(A) receptorChristoph Joesch, Emelie Guevarra, Serge P Parel, et al.
Combinatorial Chemistry & High Throughput Screening|December 8, 2004
High throughput screening of beta-amyloid secretion inhibitors using homogenous time-resolved fluorescenceHugo Albrecht, Peter Zbinden, Andrea Rizzi, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 12, 2005
Metabolism and disposition of imatinib mesylate in healthy volunteersHans-Peter Gschwind, Ulrike Pfaar, Felix Waldmeier, et al.
Science Advances|May 24, 2023
Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant EnterobacteriaceaeMatthias Schuster, Emile Brabet, Kathryn K Oi, et al.
Nature|November 24, 2019
Author Correction: Chimeric peptidomimetic antibiotics against Gram-negative bacteriaAnatol Luther, Matthias Urfer, Michael Zahn, et al.
Nature|October 25, 2019
Chimeric peptidomimetic antibiotics against Gram-negative bacteriaAnatol Luther, Matthias Urfer, Michael Zahn, et al.
Pageof 1